GlassScriptPhysician profile
Christopher Bahy Ibrahim
NPI 1205065125
$5,799.28
in general payments reported to CMS, 2019-2025
35 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $164 · 2021: $956 · 2022: $880 · 2023: $991 · 2024: $969 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,975 · Education: $25.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,974.61 |
| Education | $25.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,576.60 | 2019-2025 | |
| Janssen Biotech, INC. | $585.24 | 2019-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $442.37 | 2019-2025 | Entyvio |
| Celgene Corporation | $427.06 | 2021-2024 | Zeposia |
| Pfizer INC. | $362.08 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $295.23 | 2022-2025 | Dupixent |
| Genzyme Corporation | $231.68 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.12 | 2019-2024 | Trulance, Xifaxan |
| Intercept Pharmaceuticals, INC. | $159.81 | 2019-2025 | Ocaliva |
| Ardelyx, INC. | $151.64 | 2023-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $138.19 | 2024-2025 | Iqirvo |
| Gilead Sciences, INC. | $105.74 | 2019-2023 | |
| Qol Medical, LLC | $104.37 | 2019-2024 | Sucraid, Sucraid |
| Janssen Scientific Affairs, LLC | $94.48 | 2019 | |
| Biohorizons Implant Systems INC. | $90.05 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $83.86 | 2019-2024 | Injectafer |
| Ferring Pharmaceuticals INC. | $81.68 | 2020-2024 | Rebyota |
| Ironwood Pharmaceuticals, INC | $74.65 | 2020-2024 | |
| Nestle Healthcare Nutrition INC. | $63.59 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $60.72 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $56.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $47.29 | 2021 | |
| Amgen INC. | $47.19 | 2023-2025 | Avsola, Amjevita, Uplizna |
| Mallinckrodt Hospital Products INC. | $41.60 | 2022-2024 | Terlivaz |
| Novo Nordisk INC | $38.22 | 2025 | Wegovy |
| Endo Pharmaceuticals INC. | $33.46 | 2019 | |
| Shionogi INC | $32.90 | 2019 | |
| Lilly USA, LLC | $27.90 | 2024 | Omvoh |
| Celltrion USA INC. | $25.96 | 2024 | Zymfentra |
| Ucb, INC. | $23.09 | 2019 | |
| Pharmacosmos Therapeutics INC. | $19.26 | 2024 | Monoferric |
| Recordati_rare_diseases_inc. | $19.22 | 2025 | Panhematin |
| Aimmune Therapeutics, INC. | $16.94 | 2025 | Vowst |
| Merck Sharp & Dohme LLC | $13.81 | 2024 | Dificid, Zerbaxa |
| Evoke Pharma, INC. | $13.52 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.